AbbVie tops earnings estimates, sticks with 2020 guidance [MarketWatch]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: MarketWatch
AbbVie Inc. said Friday it had net income of $3.010 billion, or $2.02 a share, in the first quarter, up from $2.456 billion, or $1.65 a share, in the year-earlier period. Adjusted per-share earnings came to $2.42, ahead of the $2.25 FactSet consensus. The biopharmaceutical company said revenue rose to $8.619 billion from $7.828 billion, also ahead of the FactSet consensus of $8.325 billion. U.S. sales of Humira rose 13.7% to $3.656 billion, while international sales fell 14.9% to $1.047 billion, due to competition from biosimilars. Revenue from the company's hematologic oncology portfolio rose 32% to $1.549 billion. The company lowered its guidance for 2020 EPS to a range of $7.60 to $7.70 from a prior range of $7.66 to $7.76. It is sticking with its guidance for 2020 adjusted EPS of $9.61 to $9.71. The company said its supporting COVID-19 research by working with health officials to see if its Kaletra/Aluvia HIV therapy can be effective against the virus. It has also launched a Phase
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie-Sponsored Symposium at ESMO Asia 2025 Highlights Urgent Medical Need in Platinum-Resistant Advanced Ovarian Cancer [Yahoo! Finance]Yahoo! Finance
- AbbVie Inc. (ABBV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers [Yahoo! Finance]Yahoo! Finance
- AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood CancersPR Newswire
- AbbVie: Increased Outlook For 2025 And Expansions Merit Continued "Strong Buy" Rating [Seeking Alpha]Seeking Alpha
ABBV
Earnings
- 10/31/25 - Beat
ABBV
Sec Filings
- 11/20/25 - Form F-6
- 11/4/25 - Form 10-Q
- 10/31/25 - Form 8-K
- ABBV's page on the SEC website